Our comprehensive guide hospitals information helps you quickly locate a hospital anywhere in the world. Our database contains in excess of 16,000 hospitals, making it one of the best places to find information on the hospital you are searching for. To assist you with locating a hospital, you can refine your search by selecting the country in which the hospital is located and choose to search by either hospital name, city/town or state/county.

 Home>> Increlex (mecasermin)

Increlex (mecasermin)

General Information

Increlex (mecasermin) contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1). It is designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normalized statural growth. Patients with severe primary IGF-1 deficiency (Primary IGFD) fail to produce adequate levels of IGF-1, due to disruption of the growth hormone (GH) pathway used to promote IGF-1 release (possible GH pathway disruptions include mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects).

Increlex is specifically indicated for the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.

Increlex is supplied as a sterile, aqueous, clear and colorless solution intended for subcutaneous injection. Dosing should be titrated on a per-patient basis: the recommended initial dose is 40-80 mcg/kg twice daily. The dose can be increased in 40 mcg/kg/dose increments if well tolerated for one week, to a maximum dose of 120 mcg/kg twice daily.


Additional Information

For additional information regarding Increlex or growth failure due to Primary IGFD, please visit the Increlex web page.


Clinical Results

FDA Approval
Approval of Increlex was based on five clinical trials of the drug: four were open-label studies, and one was double-blind and placebo-controlled. The studies enrolled a total of 71 children suffering from extreme short stature; all children exhibited symptoms of Primary IGFD, including slow growth rates, low IGF-1 serum concentrations, and normal growth hormone secretion. Pooled results from these studies indicated that administration of Increlex increased height velocity significantly compared to baseline for years 1 through 6:


  • Year 1: + 5.2 cm/year, n=58, p<0.0001
  • Year 2: + 2.9 cm/year, n=48, p<0.0001
  • Year 3: + 2.3 cm/year, n=38, p<0.0001
  • Year 4: + 1.5 cm/year, n=23, p=0.0045
  • Year 5: + 1.5 cm/year, n=21, p=0.0015
  • Year 6: + 1.5 cm/year, n=20, p=0.0009

Increlex was also shown to increase bone maturation rate in 49 subjects, with bone age increasing 8.1% faster than chronological age (+5.3 years vs. +4.9 years).


Mechanism of Action

Increlex supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.


Literature References

Side effects

Adverse events associated with the use of Symlin may include, but are not limited to, the following:

  • Bruising
  • Lipohypertrophy
  • Otitis Media
  • Snoring
  • Headache
  • Dizziness
  • Convulsions
  • Vomiting
  • Ear pain
  • Hypoacusis
  • Cardiac Murmur
  • Arthralgia

Hypoglycemia, thought to be related to the drug's insulin-like activities, occurred in a significant portion of patients (42%) during their course of therapy. While most cases were mild or moderate, 5 subjects had severe hypoglycemia on one or more occasions, and 4 subjects experienced hypoglycemic seizures/loss of consciousness. Risk of hypoglycemia was generally mediated when a meal or snack was consumed 20 minutes prior to Increlex administration.

Also, as the drug is a pharmaceutical protein, anti-Increlex/anti-IGF-1 antibody formation can occur. 14 of 23 subjects treated for 2 years with the drug experienced some degree of anti-IGF-1 antibody formation, though no clinical consequences (allergic reaction or loss of efficacy) were observed.


Treatment

Growth Failure

Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Addyi (flibanserin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Akynzeo (netupitant and palonosetron) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Onglyza (saxagliptin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Actiq Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rebetol (ribavirin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Picato (ingenol mebutate) gel Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Bextra Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print OxyContin (oxycodone HCl controlled-release) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Propecia Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print REGRANEX (becaplermin) Gel Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Teczem (enalapril maleate/diltiazem malate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Aromasin Tablets Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Caduet (amlodipine/atorvastatin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Cayston (aztreonam for inhalation solution) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Oxtellar XR (oxcarbazepine extended release) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Arixtra Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Relpax (eletriptan hydrobromide) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Ravicti (glycerol phenylbutyrate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Amrix (cyclobenzaprine hydrochloride extended release) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Alphagan (brimonidine) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Galzin (zinc acetate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Aptivus (tipranavir) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Premarin (conjugated estrogens) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Pomalyst (pomalidomide) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print OsmoCyte Pillow Wound Dressing Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Oleptro (trazodone hydrochloride) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Arzerra (ofatumumab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Lovenox (enoxaparin sodium) Injection Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Cleocin (clindamycin phosphate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Accolate Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Prozac Weekly (fluoxetine HCl) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Olysio (simeprevir) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rituxan Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Prempro Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Abilify (aripiprazole) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Perjeta (pertuzumab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Pennsaid (diclofenac sodium topical solution) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print ReoPro